SVN-114

About SVN-114

A novel AI-discovered compound designed to modulate serotonin, dopamine and noradrenaline signalling, with the aim of supporting improved emotional processing and engagement with therapy in individuals living with trauma-related disorders.

These neurotransmitter systems are central to the neurobiology of trauma and social behaviour, and targeting them in a controlled way may open an important new therapeutic avenue for PTSD.

Intellectual property

Composition of matter patents filed internationally by Solvonis.

Mechanism of action

Novel monoaminergic modulator targeting SERT, DAT, and NET transporters.

Designed to rebalance dysregulated neurotransmission in PTSD-relevant circuits.

Progress to date

SVN-114 selected as lead candidate from discovery programme.

Composition of matter patents filed; freedom-to-operate checks completed.

In vitro and in vivo efficacy signals demonstrated.

Status and pathway

2026(f): Lead identified

2028(f): IND-enabling studies.

2029(f): IND submission.